To hear about similar clinical trials, please enter your email below
Trial Title:
Application of 68Ga-Pentixafor PET/CT for Thymoma
NCT ID:
NCT06086327
Condition:
Thymoma
Conditions: Official terms:
Thymoma
Thymus Neoplasms
Study type:
Interventional
Study phase:
Early Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
68Ga-Pentixafor
Description:
Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses
of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
Arm group label:
68Ga-Pentixafor, PET/CT
Other name:
68Ga-CXCR4
Summary:
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging-
68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma
with higher accuracy. This prospective study is going to investigate whether metabolic
characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish
evaluation for thymoma.
Detailed description:
Thymoma is 1 rare type of tumor developed on the thymic epithelium; patients with thymoma
also might have myasthenia gravis (MG). Because of the scarcity and complexity of
MG-associated thymoma, its pathogenesis and etiology still remain unclear nowadays. The
expression of C-X-C chemokine receptor type 4 (CXCR4) is absent or low in most healthy
tissues but highly expressed in various types of tumors. CXCR4 might contribute to the
clinical cancer progression, and CXCR4 could be a valuable prognostic biomarker in the
therapy of MG-associated thymoma.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- suspected or confirmed untreated thymoma patients
- signed written consent.
Exclusion Criteria:
- pregnancy
- breastfeeding
- known allergy against Pentixafor
- any medical condition that in the opinion of the investigator,may
- significantly interfere with study compliance.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Peking Union Medical College Hospitall, Chinese Academy of Medical Science and Peking Union Medical College
Address:
City:
Beijing
Zip:
100730
Country:
China
Status:
Recruiting
Contact:
Last name:
Zhaohui Zhu, MD
Phone:
+8613611093752
Email:
13611093752@163.com
Start date:
June 22, 2023
Completion date:
December 31, 2024
Lead sponsor:
Agency:
Peking Union Medical College Hospital
Agency class:
Other
Source:
Peking Union Medical College Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06086327
